Outputs (98)

Blood platelets stimulate cancer extravasation through TGFβ-mediated downregulation of PRH/HHEX (2020)
Journal Article
Marcolino De Assis, E., Siddiqui, Y. H., van den Bosch, M., Poole, A. W., Jayaraman, P.-S., & Gaston, K. (2020). Blood platelets stimulate cancer extravasation through TGFβ-mediated downregulation of PRH/HHEX. Oncogenesis, 9, Article 10. https://doi.org/10.1038/s41389-020-0189-0

Cancer cells go through a process known as epithelial–mesenchymal transition (EMT) during which they acquire the ability to migrate and invade extracellular matrix. Some cells also acquire the ability to move across a layer of endothelial cells to en... Read More about Blood platelets stimulate cancer extravasation through TGFβ-mediated downregulation of PRH/HHEX.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article
Alfarsi, L. H., El-Ansari, R., Craze, M. L., Masisi, B. K., Mohammed, O. J., Rakha, E. A., Ellis, I. O., & Green, A. R. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 21(4), Article 1407. https://doi.org/10.3390/ijms21041407

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib (2020)
Journal Article
Ali, R., Alblihy, A., Toss, M. S., Algethami, M., Al Sunni, R., Green, A. R., Rakha, E. A., & Madhusudan, S. (2020). XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 12, 175883592097420. https://doi.org/10.1177/1758835920974201

Background: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, th... Read More about XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.

Local microvascular leakage promotes trafficking of activated neutrophils to remote organs (2020)
Journal Article
Owen-Woods, C., Joulia, R., Barkaway, A., Rolas, L., Ma, B., Nottebaum, A. F., Arkill, K. P., Stein, M., Girbl, T., Golding, M., Bates, D. O., Vestweber, D., Voisin, M. B., & Nourshargh, S. (2020). Local microvascular leakage promotes trafficking of activated neutrophils to remote organs. Journal of Clinical Investigation, 130(5), 2301-2318. https://doi.org/10.1172/JCI133661

Copyright: © 2020, Owen-Woods et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Increased microvascular permeability to plasma proteins and neutrophil emigration are hallmar... Read More about Local microvascular leakage promotes trafficking of activated neutrophils to remote organs.

A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ (2020)
Journal Article
Mittal, K., Toss, M. S., Wei, G., Choi, D. H., Melton, B. D., Osan, R. M., Milligy, I. M., Green, A. R., Janssen, E. A., Søiland, H., Gogineni, K., Manne, U., Rida, P., Rakha, E. A., & Aneja, R. (2020). A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ. Clinical Cancer Research, 26(12), 2898-2907. https://doi.org/10.1158/1078-0432.ccr-19-1272

Blood Vessels Under the Microscope (2020)
Journal Article
Machado, M. J. C., Mitchell, C. A., Franklin, J., Thorpe, A., & Rutland, C. S. (2020). Blood Vessels Under the Microscope. Frontiers for Young Minds, 7, Article 151. https://doi.org/10.3389/frym.2019.00151

This paper looks at blood vessels. All humans and animals have blood vessels, including your pet rabbit or dog, a whale or a giraffe! We need blood vessels to stay alive. This paper answers many questions, including what blood vessels are used for an... Read More about Blood Vessels Under the Microscope.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease (2020)
Journal Article
Gallipoli, P., Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., Brümmendorf, T., Schafhausen, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., …Copland, M. (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34, 1775–1786. https://doi.org/10.1038/s41375-019-0700-9

© 2020, The Author(s), under exclusive licence to Springer Nature Limited. In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are responsible for disease persistence despite TKI. Based on in vitro data, CHOIC... Read More about A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer (2020)
Journal Article
Vangangelt, K. M., Green, A. R., Heemskerk, I. (. F., Cohen, D., Van Pelt, G. W., Sobral-Leite, M., Schmidt, M. K., Putter, H., Rakha, E. A., Tollenaar, R. A., & Mesker, W. E. (2020). The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer. International Journal of Cancer, 146(8), 2296-2304. https://doi.org/10.1002/ijc.32857

The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer prognostication in clinically relevant subgroups of patients. The TSR was assessed on hematoxylin and eosin stained tissue slides of 1794 breast cancer patients fro... Read More about The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer.